clinical trial · NCT07166133
GORE® TAG® Thoracic Branch Endoprosthesis Zone 0/1 Post-Approval Study
W.L.Gore & Associates·N/A·recruiting·n = 125
Aortic Arch DissectionAortic Arch AneurysmGORE® TAG® Thoracic Branch Endoprosthesis
brief summary
A prospective multi-center post-market study collecting outcomes through at least 5-years and up to 10-years post procedure for subjects treated with the TBE Device in Zone 0/1 as part of routine clinical practice.
started
Mar 2, 2026
primary completion
Jul 1, 2028
completion
Mar 1, 2036
last updated
Jun 2, 2026
detailed description
Minimum of 125 total subjects with a TBE Device implantation procedure initiated in up to 50 Sites in the United States. Subjects will have follow-up at 1 Month, 6 Month, 1 Year, and annually thereafter for a minimum of 5-years and up to a maximum of 10 years.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol